#1 Clinical Trials Search in Europe

Humanised Igg1 Monoclonal Antibody Against Muscle Specific Kinase

A new drug called ARGX-119, which contains a humanized IgG1 monoclonal antibody against muscle-specific kinase, is being studied in clinical trials for the treatment of Amyotrophic Lateral Sclerosis (ALS). This article provides an overview of the ongoing research, including the study design, eligibility criteria, and potential benefits for ALS patients.

Table of Contents

What is ARGX-119?

ARGX-119 is a new medication being developed to treat Amyotrophic Lateral Sclerosis (ALS), a serious neurological condition. It is classified as a humanised IgG1 monoclonal antibody that targets a specific protein called muscle-specific kinase.[1]

To break this down:

  • Humanised means the antibody has been engineered to be similar to human antibodies, reducing the chance of the body rejecting it.
  • IgG1 refers to a type of antibody that our immune system naturally produces.
  • Monoclonal antibody means it’s a laboratory-created molecule that is designed to target a specific structure in the body.
  • Muscle-specific kinase is a protein involved in the communication between nerves and muscles.

ARGX-119 is administered as a concentrate for solution for infusion, which means it’s given directly into the bloodstream through an IV drip.[1]

Target Condition: Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurological disease that affects nerve cells in the brain and spinal cord. It causes the motor neurons to degenerate and die, leading to a loss of muscle control and eventually paralysis.[1]

Symptoms of ALS may include:

  • Muscle weakness
  • Difficulty speaking or swallowing
  • Muscle twitching or cramping
  • Difficulty with physical activities

Currently, there is no cure for ALS, which is why research into new treatments like ARGX-119 is crucial.

Clinical Trial Overview

A clinical trial is currently underway to evaluate ARGX-119 for the treatment of ALS. This trial is known as a Phase 2a study, which means it’s testing the drug’s effectiveness and safety in a relatively small group of patients with ALS.[1]

The official title of the study is: “A Phase 2a, Double-Blinded, Randomized, Placebo-Controlled, and Active-Treatment Extension Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of ARGX-119 in Participants With Amyotrophic Lateral Sclerosis”.[1]

Eligibility Criteria

To participate in this study, patients must meet certain criteria. Some key inclusion criteria are:[1]

  • Age: Between 18 and 80 years old
  • Diagnosis: Must have a confirmed diagnosis of ALS (either familial or sporadic) according to Gold Coast criteria
  • Disease progression: Must have a specific risk profile score
  • Lung function: Must have a certain level of lung capacity

Some key exclusion criteria include:[1]

  • Extensive use of ventilation support
  • Previous exposure to gene or cell therapies for ALS
  • Pregnancy or intention to become pregnant during the study

Study Design

The study is designed as follows:[1]

  • Double-blinded: Neither the patients nor the researchers know who is receiving the actual drug or a placebo during the initial phase.
  • Randomized: Participants are randomly assigned to different groups.
  • Placebo-controlled: Some participants will receive a placebo (a substance with no active ingredients) for comparison.
  • Active-Treatment Extension: After the initial phase, all participants will receive the actual drug.

The study involves different dosage levels of ARGX-119, administered intravenously (through a vein).[1]

Objectives and Endpoints

The main objectives of this study are:[1]

  1. To evaluate the safety and tolerability of ARGX-119 in ALS patients
  2. To assess how effective ARGX-119 is in slowing down the progression of ALS
  3. To understand how the drug behaves in the body (pharmacokinetics) and how the immune system responds to it (immunogenicity)

The study will measure several outcomes, including:[1]

  • Adverse events (side effects)
  • Changes in laboratory tests, ECGs, and vital signs
  • Changes in the number of motor units (groups of muscle fibers controlled by a single nerve cell)
  • Presence of antibodies against ARGX-119 in the blood

Potential Benefits and Considerations

While ARGX-119 shows promise, it’s important to remember that it’s still in the experimental stage. The potential benefits include:[1]

  • Possible slowing of ALS progression
  • Contributing to the advancement of ALS research
  • Access to a new potential treatment before it’s widely available

However, there are also considerations to keep in mind:

  • As with any experimental treatment, there may be unknown side effects
  • The treatment may not be effective for everyone
  • Participation in the study requires time commitment and regular medical visits

If you or a loved one has ALS and is interested in this clinical trial, it’s crucial to discuss it with your healthcare provider. They can provide more information and help determine if this study might be appropriate for your specific situation.

Aspect Details
Drug Name ARGX-119 (Humanised IgG1 Monoclonal Antibody Against Muscle Specific Kinase)
Condition Studied Amyotrophic Lateral Sclerosis (ALS)
Study Phase Phase 2a
Study Design Double-blinded, randomized, placebo-controlled with active-treatment extension
Primary Objectives Evaluate safety and tolerability of ARGX-119 in ALS participants
Secondary Objectives Assess efficacy on electrophysiological measures, pharmacokinetics, and immunogenicity
Key Eligibility Criteria Age 18-80, diagnosed with ALS, specific TRICALS risk profile, adequate lung function
Administration Method Intravenous infusion
Primary Endpoints Adverse events, clinical laboratory tests, ECGs, and vital signs
Secondary Endpoints Changes in motor unit number, pharmacokinetics, anti-drug antibody development

FAQ

  • What is ARGX-119? ARGX-119 is an investigational drug containing a humanized IgG1 monoclonal antibody that targets muscle-specific kinase. It is being studied as a potential treatment for Amyotrophic Lateral Sclerosis (ALS).
  • What is the main objective of the clinical trial? The main objective of the clinical trial is to evaluate the safety and tolerability of ARGX-119 in participants with ALS.
  • Who is eligible to participate in the trial? Eligible participants must be between 18 and 80 years old, diagnosed with familial or sporadic ALS according to Gold Coast criteria, have a specific TRICALS risk profile, and meet certain lung function requirements.
  • How is the drug administered? ARGX-119 is administered intravenously as a concentrate for solution for infusion.
  • What are the key outcomes being measured in the trial? The trial is measuring adverse events, clinical laboratory tests, ECG and vital signs, changes in motor unit number, pharmacokinetics of ARGX-119, and the development of anti-drug antibodies.

Ongoing Clinical Trials on Humanised Igg1 Monoclonal Antibody Against Muscle Specific Kinase

  • Study on the Safety and Efficacy of ARGX-119 for Adults with Amyotrophic Lateral Sclerosis (ALS)

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark France The Netherlands Sweden

Glossary

  • Amyotrophic Lateral Sclerosis (ALS): A progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing loss of muscle control.
  • Humanized IgG1 Monoclonal Antibody: A type of laboratory-created antibody designed to target a specific protein in the body, in this case, muscle-specific kinase.
  • Muscle-Specific Kinase: An enzyme important for the formation and maintenance of the neuromuscular junction, where nerves connect to muscles.
  • TRICALS risk profile: A scoring system used to assess the risk and progression of ALS in patients.
  • SVC (Slow Vital Capacity): A measure of lung function that assesses the amount of air a person can slowly exhale after taking a deep breath.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Anti-drug antibodies (ADA): Antibodies produced by the body's immune system in response to a therapeutic drug, which can affect the drug's efficacy and safety.
  • Electrophysiological muscle scan (MScan): A technique used to assess muscle function and health by measuring electrical activity in muscle tissue.
  • Motor unit number (MUN): An estimate of the number of functioning motor units (a motor neuron and the muscle fibers it controls) in a muscle.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-efficacy-of-argx-119-for-adults-with-amyotrophic-lateral-sclerosis-als/